U.S. v. Eli Lilly and Co.

Zyprexa Plea Agreement by Eli Lilly Over Marketing Drug For Unapproved Use
January 15, 2009

Email This

  • Eugene Thirolf, DOJ’s Consumer Litigation Director
  • Nina Gussack, for Eli Lilly
  • Product Liability Lawyers

  • Related Links:
  • Injury and Accident Center

  • Drugmaker Eli Lilly and Company agrees to pay $1.415 billion for off-label marketing of the company’s Zyprexa drug.

    Although Zyprexa was approved for treating schizophrenia and certain types of bipolar disorder, Lilly admitted marketing the drug for other unapproved uses like the treatment of dementia.

    You can read the plea agreement below.


    Ads by FindLaw